HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Helena Skalnikova Selected Research

bohemine

2/2011Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application.
8/2005Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Helena Skalnikova Research Topics

Disease

2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
02/2011 - 08/2005
2Neoplasms (Cancer)
02/2011 - 08/2005
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2020

Drug/Important Bio-Agent (IBA)

2bohemineIBA
02/2011 - 08/2005
2Proteins (Proteins, Gene)FDA Link
02/2011 - 08/2005
1Small Interfering RNA (siRNA)IBA
01/2020
1rho Guanine Nucleotide Dissociation Inhibitor betaIBA
02/2011
1Daunorubicin (Cerubidine)FDA LinkGeneric
02/2011
1Pharmaceutical PreparationsIBA
02/2011
1Phosphotransferases (Kinase)IBA
02/2011
1Vincristine (Oncovin)FDA LinkGeneric
02/2011
1CyclinsIBA
02/2011
1ProteomeIBA
02/2011
1Y-Box-Binding Protein 1IBA
02/2011
1Biomarkers (Surrogate Marker)IBA
08/2005
1ChromatinIBA
08/2005
1Cyclin-Dependent Kinases (cdk Proteins)IBA
08/2005
1Histones (Histone)IBA
08/2005